4麦垚 刘湘源.系统性硬化症134例床分析.Chinese General Praetice,2001,4(3):246-246.
5Gilmar F P, Richard P A, Virgina M F, et al. Sleep disruption in systemic sclerosis (seleroderma) patients: clinical and polysomnographic findings [J]. Sleep Medicine, 2002, 3. 341 - 345.
10Predrag Ostojic, Nemanja Damjanov. Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis [J]. Clin Rheumatol, 2005, Nov (1) : 1 - 5.
4Roger H, Agneta S, Anita A. Mortality and causes of death in a Swedish series of systemic sclerosis patients [ J ]. Ann Rheum Dis, 1998, 57:682 - 686.
6Tunothy JL, Brenda WG, Mary BT, et al. Racial differences in scleroderma among women in Michigan[J]. Arthritis Rheum,1997,20(4) :734 - 742.
7Kuwana M, Kaburaki J, Okano T, et al. Clinical associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis[J]. Arthritis Rheum, 1994,37(1) :75 - 83.
8Subcommittee for scleroderma criteria of the American Rheumatism Associations Diagnostic and Therapeutic Criteria Committee[J]. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Pdaeum, 1980,23(4) :581 - 590.
9Gabriele V, Carol B. Systemic sclerosis [ J]. Clin Rheum.2002, 16(5) :807 - 816.
10Frank CA, Robert FH, Filemon T, et al. Increased prevalence of systemic sclerosis in a native American tribe in Oklahoma[J].Arthritis Rheum, 1996,39(8):1362- 13.70.
6Villalta D, Bizzaro N, Platzgummer S, et al. Accuracy of semiquantitative immunoenzymatic methods in quantitation of anti - topoisomerase I (Scl-70) antibodies[J]. Clin Rheumatol, 2005,24(5) :453-459.
7Hayakawa I, Hasegawa M, Takehara K, et al. Anti-DNA topoisomerase IIα autoantibodies in Japanese patients with systemic sclerosis [J].Arch Dermatol Res, 2005,297 (4): 180-183.
